Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 8/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CCNH | P51946 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935837 | 0.90 | CDK4 (0.54) | CDK2KCNH2CDK1CDK4CDK6 | |
| Hydrochloric Acid SCHEMBL4246512 | 0.90 | CDK4 (0.53) | CDK2KCNH2CDK1CDK4CDK6 | |
| SCHEMBL3938139 | 0.88 | CDK2 (0.49) | CDK2KCNH2CDK1CCNB1 | |
| SCHEMBL4254758 | 0.88 | CDK2 (0.49) | CDK2KCNH2CDK1CDK4CDK6 | |
| SCHEMBL3945081 | 0.86 | CDK2 (0.47) | CDK2KCNH2CDK1 | |
| SCHEMBL3946434 | 0.85 | CDK2 (0.47) | CDK2KCNH2CDK1EGFRERBB3 | |
| SCHEMBL3938198 | 0.85 | CDK2 (0.51) | CDK2KCNH2CDK1 | |
| SCHEMBL4246906 | 0.85 | CDK2 (0.51) | CDK2KCNH2CDK1CDK4CDK6 | |
| SCHEMBL13878975 | 0.84 | CDK2 (0.54) | CDK2KCNH2CDK1CDK4CDK6 | |
| SCHEMBL13878974 | 0.84 | CDK2 (0.51) | CDK2KCNH2CDK1CDK4CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046782-A2 | IMIDAZOLYLPYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | Astra Zeneca AB (SE) | 2009-04-15 | — | — | EP | claimed |
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| US-20230115252-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | UNIVERSITÉ PARIS CITÉ (FR) | 2023-04-13 | — | — | US | disclosed |
| EP-3741375-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-11-25 | — | — | EP | disclosed |
| US-20200323900-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-10-15 | — | — | US | disclosed |
| US-20170209488-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| EP-3169337-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016207366-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016008966-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-01-21 | — | — | WO | disclosed |
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188502-A1 | New Compounds I | SLC10A1, REN, SLC5A1 | CDK2 3536/4885KCNH2 741/4885CDK1 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.